Dan Klein, President and CEO, Patient Access Network Foundation, discusses how the lack of a limit on cost sharing in Medicare affects patient outcomes and disease states that PAN Foundation is keeping an eye on.
Dan Klein, President and CEO, Patient Access Network Foundation, discusses how the lack of a limit on cost sharing in Medicare affects patient outcomes and disease states that PAN Foundation is keeping an eye on.
Transcript
How does the lack of a limit on cost sharing in Medicare affect patient outcomes?
Patient outcomes are really complicated as far as the various factors that affect success with therapy. Obviously out-of-pocket costs are a well-known barrier to initiating treatment and to being adherent to treatment. So, we feel that we are able to address that successfully for many patients by giving them a grant that covers their out-of-pocket costs. But, it’s not a guarantee, so what we try to do is connect patients with other support services. We have a very active alliance partner program that patients can opt into, and if they need social support or peer support or help with other challenges they’re facing because of their illness, they can often get that from 1 of our patient advocacy partners.
Are there any disease states that PAN Foundation is keeping an eye on the drugs coming down the pipeline?
We’ve looked at a number of different diseases, and every year we have opened between 6 and 8 new disease funds, new indications that we provide assistance for. Some of the ones that we look at that are what we call prospective, we publish on our website so that potential donors can see them. One area that I know we’re interested in, that we’re taking a look at now, is amyloidosis. It’s a potentially large area; it’s a little different than the typical disease area. It’s got a lot of challenges in terms of different symptoms, and we may be able to put a fund in place for that this coming year.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More